Led by the ATIC network, and supported by JDRF and NHMRC, the IAA trial will test whether the combination of two safe immune therapies called abatacept and nasal insulin, can delay the requirement for insulin injections in people with newly diagnosed type 1 diabetes.

This clinical trial is seeking participants aged between 6 and 21 years who have been diagnosed with type 1 diabetes in the last 100 days.

For more information about IAA, click here.